Advertisement
Research Article

A Candidate Gene Approach Identifies the TRAF1/C5 Region as a Risk Factor for Rheumatoid Arthritis

  • Fina A. S Kurreeman,

    Affiliation: Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands

    X
  • Leonid Padyukov,

    Affiliation: Rheumatology Unit, Department of Medicine, Karolinska Institute at Karolinska Hospital, Stockholm, Sweden

    X
  • Rute B Marques,

    Affiliation: Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands

    X
  • Steven J Schrodi,

    Affiliation: Celera, Alameda, California, United States of America

    X
  • Maria Seddighzadeh,

    Affiliation: Rheumatology Unit, Department of Medicine, Karolinska Institute at Karolinska Hospital, Stockholm, Sweden

    X
  • Gerrie Stoeken-Rijsbergen,

    Affiliation: Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands

    X
  • Annette H. M van der Helm-van Mil,

    Affiliation: Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands

    X
  • Cornelia F Allaart,

    Affiliation: Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands

    X
  • Willem Verduyn,

    Affiliation: Department of Immunohaematology and Bloodbank, Leiden University Medical Center, Leiden, The Netherlands

    X
  • Jeanine Houwing-Duistermaat,

    Affiliation: Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands

    X
  • Lars Alfredsson,

    Affiliation: Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden

    X
  • Ann B Begovich,

    Affiliation: Celera, Alameda, California, United States of America

    X
  • Lars Klareskog,

    Affiliation: Rheumatology Unit, Department of Medicine, Karolinska Institute at Karolinska Hospital, Stockholm, Sweden

    X
  • Tom W. J Huizinga,

    Affiliation: Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands

    X
  • Rene E. M Toes mail

    To whom correspondence should be addressed. E-mail: R.E.M.Toes@lumc.nl

    Affiliation: Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands

    X
  • Published: September 18, 2007
  • DOI: 10.1371/journal.pmed.0040278

About the Authors

Fina A. S Kurreeman, Rute B Marques, Gerrie Stoeken-Rijsbergen, Annette H. M van der Helm-van Mil, Cornelia F Allaart, Tom W. J Huizinga, Rene E. M Toes
Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
Leonid Padyukov, Maria Seddighzadeh, Lars Klareskog
Rheumatology Unit, Department of Medicine, Karolinska Institute at Karolinska Hospital, Stockholm, Sweden
Steven J Schrodi, Ann B Begovich
Celera, Alameda, California, United States of America
Willem Verduyn
Department of Immunohaematology and Bloodbank, Leiden University Medical Center, Leiden, The Netherlands
Jeanine Houwing-Duistermaat
Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands
Lars Alfredsson
Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden

Corresponding Author

Email: R.E.M.Toes@lumc.nl

Competing Interests

Drs. Begovich and Schrodi own stock options in Applied Biosystems and Celera Genomics. The remaining authors have declared no conflicts of interest.

Author Contributions

FASK, LP, SJS, LA, LK, TWJH, and REMT designed the study. FASK, LP, SJS, GSR, AHM, JHD, ABB, LK, TWJH, and REMT analyzed the data. AHM, CFA, WV, LA, ABB, LK, TWJH, and REMT enrolled patients. FASK, LP, RBM, CFA, WV, JHD, LA, ABB, LK, TWJH, and REMT contributed to writing the paper. FASK, LP, RBM, SJS, MS, GSR, CFA, LA, ABB, LK, TWJH, and REMT collected data or performed experiments for this study. MS genotyped Swedish patients and controls. CFA provided data and material of one of the cohorts investigated in this paper, being the principal investigator of the study that included the patients in this cohort, and assisted with the interpretation of clinical data. LA was principal investigator (together with LK) of EIRA, the largest of the studies that was used for replication. LA was responsible for the design of EIRA and also for the organization of data collection. LK contributed to the collection of patients and controls in the Swedish EIRA study.